Stay updated on Quizartinib vs. Salvage Chemo in FLT3-ITD+ AML Clinical Trial
Sign up to get notified when there's something new on the Quizartinib vs. Salvage Chemo in FLT3-ITD+ AML Clinical Trial page.

Latest updates to the Quizartinib vs. Salvage Chemo in FLT3-ITD+ AML Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe ClinicalTrials.gov record for the QuANTUM-R study is displayed, including its design, eligibility criteria, locations, outcomes, and supporting documents.SummaryDifference100%

- Check18 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.2 to v3.8.0; the study record remains unavailable on the page.SummaryDifference0.2%

- Check25 days agoChange DetectedA notice appears above the page stating that NIH is transitioning from the term “Artificial Intelligence” to “Super Intelligence” and linking to updates and FAQs.SummaryDifference1%

- Check32 days agoChange DetectedThe footer revision identifier changed from v3.7.1 to v3.7.2 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check39 days agoChange DetectedThe clinical trial study record has been replaced by a 403 Forbidden error page.SummaryDifference17%

- Check46 days agoChange DetectedThe study record is displayed with its design, quizartinib and salvage-chemotherapy arms, outcomes, eligibility criteria, locations, and data-sharing information.SummaryDifference100%

Stay in the know with updates to Quizartinib vs. Salvage Chemo in FLT3-ITD+ AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Quizartinib vs. Salvage Chemo in FLT3-ITD+ AML Clinical Trial page.